Navigation Links
Perrigo Expands Infant Formula Distribution in China With Brilite Nutritionals (Shanghai) Co., Ltd.
Date:11/8/2011

ALLEGAN, Mich., Nov. 8, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has entered into Cooperation and License agreements with Brilite Nutritionals (Shanghai) Co., Ltd. ("Brilite"), a Shanghai based infant nutrition company. Under these agreements, Perrigo will supply its Bright Beginnings™ infant formula brand to Brilite, which will exclusively source all its infant formula requirements from Perrigo's U.S. manufacturing facilities, for sale and distribution in Greater China. Shipping begins immediately.  

Perrigo Chairman and CEO Joseph C. Papa stated, "This is the second agreement for premium infant formula distribution in China that Perrigo has signed in the last few weeks with more agreements to come soon. Infant formula is a new category for Brilite and we are proud to be their exclusive supplier. Brilite's proven executive team, innovative marketing, and retail distribution capabilities, will enhance the growth of our established brand."

Charlie Li, Spokesperson for Brilite Nutritionals added, "We are thrilled about this partnership with Perrigo and are confident that, together, we will build Bright Beginnings into one of the leading premium infant formula brands in the Greater China markets."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016 For hospitals considering enrollment ... already participating in the program, the Health Resources and ... as the , Mega-Guidance , could have significant impact ... published in September 2016. Essential Insights , ... Marketing , summarizes the Mega-Guidance,s key proposed changes, including ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... to achieve significant growth as next generation systems ... and use radiology for cancer surgery. New systems ... radiological overdosing that has been such a problem ... be delivered. Radiosurgery robots take cancer surgery far ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... ... ... Stuart Bentkover, MD, FACS is thrilled to announce the arrival of ... removal today, Dr. Bentkover is the only doctor in Central Massachusetts to offer patients ... approved by the Food and Drug Administration (FDA) as a safe and efficient method ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June ... Diseases, a continuing medical education (CME) event presented by the Association for Comprehensive ... a first for ACCORD, whose mission is to provide education, tools, and resources ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater ... having a tankless water heater. To view the report, click here or ... tankless. While each has their pros and cons, the type chosen is almost entirely ...
Breaking Medicine News(10 mins):